Full Press Release Details
PHILADELPHIA,May 2, 2025/PRNewswire/ --Darnatein, a subsidiary ofOSR Holdings, Inc.(NASDAQ:OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking placeMay 2–6, 2025, at theUniversity of PennsylvaniainPhiladelphia.
The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year's program highlights novel technologies and fundamental research in tissue and organ regeneration. (https://www.14thbmpconference2025.com/)
Dr. Senyon "Teddy" Choe, CEO of Darnatein, will deliver a scientific presentation onMay 3, titled:"Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration."
The presentation will showcase Darnatein's proprietary platform technology that has led to the development ofDRT-101andDRT-102, two novel biologic candidates engineered to function as BMP super-agonists. DRT-101 with good preclinical safety profiles is being developed forjoint cartilage regeneration, while DRT-102 is focused onspinal bone repair.
"This presentation reflects Darnatein's growing leadership in synthetic regenerative biologics," said Dr. Choe. "Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors with potential to transform musculoskeletal repair."
Darnatein's participation at the BMP Conference underscores a year of significant progress, including:
The company remains committed to expanding itsDesign-Augmented Biologicsplatform to address unmet needs in regenerative medicine globally.
About Darnatein
Darnateinis a biotechnology subsidiary ofOSR Holdings, Inc. (NASDAQ:OSRH)focused on the development ofdesign-augmented biologicsfor regenerative medicine. The company's proprietary platform harnesses synthetic biology and protein engineering to create next-generation growth factors for musculoskeletal and tissue repair. Lead candidates DRT-101 and DRT-102 are being developed for joint cartilage and spinal bone regeneration, respectively.
About OSR Holdings
OSR Holdings, Inc. (NASDAQ:OSRH)is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer ("Vaximm"), (ii) developing design-augmented biologics for age-related and other degenerative diseases ("Darnatein") and (iii) neurovascular intervention medical device and systems distribution in Korea ("RMC"). OSR's vision is to acquire and operate a portfolio of innovative healthcare related companies globally.
Contact:[email protected]
SOURCE OSR Holdings Inc.